Hennion & Walsh Asset Management, Inc. Syndax Pharmaceuticals Inc Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.59 Billion
- Q3 2025
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 54,698 shares of SNDX stock, worth $851,647. This represents 0.03% of its overall portfolio holdings.
Number of Shares
54,698
Previous 32,185
69.95%
Holding current value
$851,647
Previous $301,000
179.4%
% of portfolio
0.03%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding SNDX
# of Institutions
248Shares Held
100MCall Options Held
1.28MPut Options Held
1.29M-
Kynam Capital Management, LP Princeton, NJ8.52MShares$133 Million9.53% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$123 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY5.8MShares$90.3 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.03MShares$78.4 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.07MShares$63.3 Million3.84% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $881M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...